InvAscent, a private equity firm based in Hyderabad, is adapting to the evolving landscape of the pharmaceutical sector by significantly increasing its investment size. The firm’s shift comes as companies face mounting regulatory and manufacturing costs, necessitating larger capital infusions. This strategic pivot positions InvAscent to better support growth in an industry ripe for innovation.
Larger Investments for Greater Impact
In an interview, founder and chairman Hari Buggana revealed that the firm’s investment sizes have escalated to between $80 million and $100 million per deal, a notable increase from the previous range of $30 million to $50 million. This shift reflects the growing financial requirements of pharmaceutical companies that must meet stringent regulatory standards and modernize their facilities.
As the healthcare landscape transforms, InvAscent is also expanding its focus beyond traditional pharmaceuticals to include health-tech investments. This diversification aligns with broader market trends driven by escalating healthcare needs and increased consumer spending.
Changing Landscape of Healthcare Investment
The surge in investor interest in the pharmaceutical and healthcare sectors is fueled by several factors, including rising income levels, enhanced healthcare coverage, and increased medical tourism. These elements are creating new demand for innovative solutions, particularly in tier II and III cities across India.
InvAscent’s investment strategy is centered on three key sectors: pharmaceuticals, which constitute about 50% of its portfolio, healthcare at approximately 30%, and related industries such as med-tech and health-tech, making up the remaining 20%. This strategic allocation allows the firm to capitalize on various growth opportunities within the healthcare ecosystem.
Fund Growth and Domestic Investor Interest
The firm recently closed its fourth fund, which boasts a corpus of $304 million and is expected to reach $400 million with additional co-investments. So far, InvAscent has deployed around 40% of this capital. Notably, a third of the capital commitments for this fund came from domestic investors, marking a significant shift in interest from local markets.
Buggana noted that while the firm has historically attracted international investors from the U.S., Europe, and Asia, the recent influx of domestic funding reflects a growing desire among local investors to access high-quality pharmaceutical and healthcare assets.
Evolving Exit Strategies
As ticket sizes and fund sizes grow, InvAscent is also adapting its exit strategies. The firm is increasingly recognizing public markets as viable exit routes, thanks to favorable valuations for its portfolio companies. Buggana indicated that the firm anticipates at least one IPO annually from its third fund, a marker of its confidence in the market’s receptivity to high-quality healthcare assets.
Previously, InvAscent relied on exits through sales to larger private equity firms or strategic buyers. Recent successful exits include the stakes in Oliva Skin & Hair Clinic and Oasis Fertility, as well as the sale of Comprehensive Prosthetics and Orthotics to NorthCreek and Parkway Partners. The firm has demonstrated flexibility in its approach, adapting to the changing dynamics of both private and public markets.
Ongoing Investment and Support for Growth
Since its establishment in 2005, InvAscent has made approximately 39 investments and exited 20 companies, managing over $850 million in assets. The firm is particularly focused on addressing the capital needs of small and medium enterprises that often struggle to secure funding from traditional banking channels.
InvAscent provides comprehensive support to its portfolio companies, focusing on capital allocation, scaling operations, and enhancing governance. This holistic approach aims to prepare firms for sustainable growth, often targeting a scale three to four times larger than when InvAscent initially invests.
Key Takeaways
- InvAscent has significantly increased its investment sizes in the pharmaceutical sector, now participating in deals ranging from $80 million to $100 million.
-
The firm is diversifying its portfolio to include health-tech investments, reflecting changing market dynamics and consumer needs.
-
A notable proportion of capital for the latest fund has come from domestic investors, highlighting growing local interest in the healthcare sector.
-
Public markets are becoming a prominent exit route for InvAscent, with expectations of annual IPOs from its portfolio.
-
The firm continues to support small and medium enterprises by addressing their capital needs and enhancing operational efficiency.
In conclusion, InvAscent’s strategic shift in investment size and focus reflects a broader trend of increasing costs and opportunities in the pharmaceutical sector. By adapting to market demands and expanding its approach, InvAscent is well-positioned to foster innovation and growth within the healthcare landscape. The firm’s commitment to supporting local enterprises while pursuing lucrative exits further solidifies its role as a key player in the evolving investment environment.
Read more → www.livemint.com